Nayereh Ghoreishi Nayereh Ghoreishi

Ms. Nayereh Ghoreishi Nayereh Ghoreishi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMark Cannon
Mark Cannon
EDElizabeth Dempsey
Elizabeth Dempsey
ACAshlee Cosantino
Ashlee Cosantino
NGNayereh Ghoreishi Nayereh Ghoreishi
Nayereh Ghoreishi Nayereh Ghoreishi
This study aimed to evaluate the effects of continuous xylitol administration via a subcutaneous osmotic minipump in a B16F10 syngeneic mouse model, including histological examination and metabolomic analysis. The B16F10 syngeneic model for human melanoma consisted of 6–8-week-old C57BL/6 male mice subcutaneously injected with five × 105 B16F10 cells suspended in 100 μl PBS in the right flank. The mice were randomly assigned to two groups: Group 1 was the treatment group, which received 10% xylitol-loaded pumps (n = 10), while Group 2 was the control group, which received saline-loaded pumps (n = 10). Alzet minipumps were implanted subcutaneously in the left flank of B16F10-injected mice once more than 50% of all mice developed palpable tumors. After pump implantation surgery, the mice were monitored daily and weighed twice to three times per week. Tumor sizes were measured with calipers 2–3x per week, and all mice were euthanized when their tumors became too large (20 mm on any axis or 2,000 mm3). The tumor size was reduced by approximately 35% by volume in the xylitol-treated group. The xylitol group may have a longer survival time, but this was not statistically significant (Kaplan-Meier). The metabolomic analysis suggests that xylitol significantly alters the tumor’s metabolism, potentially enhancing the host immune response.

10 January 2025 in Nutraceuticals
Verified
Journal Article
Open access
PDF file
MCMark Cannon
Mark Cannon
ACAshlee Cosantino
Ashlee Cosantino
LTLori Tran
Lori Tran
NCNavdeep S. Chandel
Navdeep S. Chandel
NGNayereh Ghoreishi Nayereh Ghoreishi
Nayereh Ghoreishi Nayereh Ghoreishi
This study investigates the effects of xylitol, a natural sugar alcohol, on tumor progression in syngeneic mouse cancer models. Xylitol is known for its dental health benefits, but emerging evidence suggests broader biological roles, including potential anti-cancer properties. We explored xylitol’s impact on two mouse cancer models: 4T1 mammary carcinoma and B16F10 melanoma. Xylitol’s efficacy in inhibiting cancer cell lines and modulating tumor progression was assessed using immunocompetent female mice. The experiments involved intratumoral and peritumoral administration of a 20% xylitol solution in two mouse strains: BALB/c (4T1 mammary carcinoma) and C57BL/6 (B16F10 melanoma). Tumor volume, histopathology, and metabolomic analyses were conducted to gauge xylitol’s influence. The study revealed that xylitol administration initially reduced tumor growth in the B16F10 melanoma model, accompanied by alterations in tumor metabolism. However, similar effects were not observed in the 4T1 mammary carcinoma model, and melanoma tumor growth re-commenced in the melanoma model after stroma deterioration caused xylitol solution leakage. These findings suggest that xylitol may have potential as an adjunct therapy in cancer treatment, specifically in melanoma. The differential response between the two cancer models underscores the complexity of cancer biology and the need for further investigation into xylitol’s mechanisms of action and its role in cancer therapy.

3 November 2025 in Nutraceuticals
Verified
Journal Article
Open access
PDF file
MCMark Cannon
Mark Cannon
EDElizabeth Dempsey
Elizabeth Dempsey
ACAshlee Cosantino
Ashlee Cosantino
NGNayereh Ghoreishi Nayereh Ghoreishi
Nayereh Ghoreishi Nayereh Ghoreishi
The present study used a syngeneic mouse model of malignant melanoma to evaluate the inhibitory efficacy of continuous xylitol administration via a subcutaneous osmotic minipump. The B16F10 syngeneic model for malignant melanoma consisted of 6–8-week-old C57BL/6 male mice subcutaneously injected with 5 × 105 B16F10 cells suspended in 100 μL PBS in the right flank. The mice were randomly assigned to two groups: Group 1 was the treatment group, which received 10% w/v xylitol in saline-loaded pumps (n = 10), while Group 2 was the control group, which received saline-loaded pumps (n = 10). ALZET 2004 minipumps were implanted subcutaneously in the left flank of B16F10-injected mice once more than 50% of all mice developed palpable tumors. After pump implantation surgery, the mice were monitored daily and weighed 2–3× times per week. Tumor sizes were measured with calipers 2–3× per week, and all mice were euthanized when their tumors became too large (20 mm on any axis or 2000 mm3). The tumor size growth was reduced by approximately 35% by volume in the xylitol-treated group which was not statistically significant. The xylitol group had a longer survival time, but this was not statistically significant (Kaplan–Meier), as was the case with the survival analysis by the Cox proportional hazards model. The metabolomic analysis suggests that xylitol significantly alters the tumor’s metabolism, potentially affecting the host immune response.

12 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMark Cannon
Mark Cannon
ACAshlee Cosantino
Ashlee Cosantino
LTLori Tran
Lori Tran
NCNavdeep Chandel
Navdeep Chandel
NGNayereh Ghoreishi Nayereh Ghoreishi
Nayereh Ghoreishi Nayereh Ghoreishi
This study investigates the effects of xylitol, a natural sugar alcohol, on tumor progression in syngeneic mouse cancer models. Xylitol has been known for its dental health benefits, but emerging evidence suggests broader biological roles, including potential anti-cancer properties. We explored xylitol's impact on two mouse cancer models: 4T1 mammary carcinoma and B16F10 melanoma. Xylitol's efficacy in inhibiting cancer cell lines and modulating tumor progression was assessed using immunocompetent female mice. The experiments involved intratumoral and peri-tumoral administration of a 20% xylitol solution in two mouse strains: BALB/c (4T1 mammary carcinoma) and C57BL/6 (B16F10 melanoma). Tumor volume, histopathology, and metabolomic analyses were conducted to gauge xylitol's influence. The study revealed that xylitol administration initially reduced tumor growth in the B16F10 melanoma model, accompanied by alterations in tumor metabolism. However, similar effects were not observed in the 4T1 mammary carcinoma model, and melanoma tumor growth re-commenced after stroma deterioration permitted xylitol solution leakage. These findings suggest that xylitol may have potential as an adjunct therapy in cancer treatment, specifically in melanoma. The differential response between the two cancer models underscores the complexity of cancer biology and the need for further investigation into xylitol's mechanisms of action and its role in cancer therapy.